dofequidar has been researched along with sdz psc 833 in 8 studies
| Studies (dofequidar) | Trials (dofequidar) | Recent Studies (post-2010) (dofequidar) | Studies (sdz psc 833) | Trials (sdz psc 833) | Recent Studies (post-2010) (sdz psc 833) |
|---|---|---|---|---|---|
| 40 | 2 | 5 | 455 | 55 | 66 |
| Protein | Taxonomy | dofequidar (IC50) | sdz psc 833 (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.3969 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuruo, T | 1 |
| Naito, M; Tsuruo, T | 2 |
| Ohno, R; Takeshita, A | 1 |
| Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T | 1 |
| Kobayashi, M; Maekawa, M; Matsui, H; Naito, K; Ohnishi, K; Ohno, R; Shigeno, K; Shinjo, K; Takeshita, A; Tanimoto, M; Yamakawa, Y | 1 |
| Hu, Y; Mizoi, K; Naitoh, Y; Sasajima, T; Satoh, T; Shimada, N; Takahashi, M | 1 |
| Hirano, I; Kiyoi, H; Maekawa, M; Matsui, H; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y; Takeshita, A; Tobita, T; Yamakage, N | 1 |
3 review(s) available for dofequidar and sdz psc 833
| Article | Year |
|---|---|
[MDR reversing drugs for clinical development].
Topics: Animals; Antineoplastic Agents; Cyclosporins; Doxorubicin; Drug Resistance; Drug Synergism; Humans; Leukemia P388; Mice; Quinolines; Verapamil | 1994 |
Therapeutic approach to drug resistant tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitomycin; Quinolines | 1998 |
[New combination therapies in hematological malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporins; Cytarabine; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Myelodysplastic Syndromes; Prednisone; Quinolines; Rituximab; Tretinoin; Vidarabine; Vincristine | 2000 |
5 other study(ies) available for dofequidar and sdz psc 833
| Article | Year |
|---|---|
New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Topics: Animals; Antineoplastic Agents; Cell Division; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Quinolines; Tumor Cells, Cultured | 1997 |
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cyclosporine; Cyclosporins; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Quinolines; Rats; Rats, Sprague-Dawley | 2002 |
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cyclosporins; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Immunotoxins; Leukemia, Myeloid; Male; Middle Aged; Quinolines; Sialic Acid Binding Ig-like Lectin 3; Tumor Cells, Cultured | 2002 |
(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Brain Neoplasms; Carcinoma 256, Walker; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Cyclosporins; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Predictive Value of Tests; Quinolines; Radiopharmaceuticals; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vincristine | 2007 |
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Count; Cell Line, Transformed; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunosuppressive Agents; Inotuzumab Ozogamicin; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Quinolines; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Tumor Cells, Cultured | 2009 |